BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23345637)

  • 1. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD.
    Velseboer DC; Broeders M; Post B; van Geloven N; Speelman JD; Schmand B; de Haan RJ; de Bie RM;
    Neurology; 2013 Feb; 80(7):627-33. PubMed ID: 23345637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease.
    Post B; Muslimovic D; van Geloven N; Speelman JD; Schmand B; de Haan RJ;
    Mov Disord; 2011 Feb; 26(3):449-56. PubMed ID: 21312273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of disability and quality of life in mild to moderate Parkinson disease.
    Muslimovic D; Post B; Speelman JD; Schmand B; de Haan RJ;
    Neurology; 2008 Jun; 70(23):2241-7. PubMed ID: 18519873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of motor impairment and disability in Parkinson disease: a population-based study.
    Alves G; Wentzel-Larsen T; Aarsland D; Larsen JP
    Neurology; 2005 Nov; 65(9):1436-41. PubMed ID: 16275832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder.
    Postuma RB; Lang AE; Gagnon JF; Pelletier A; Montplaisir JY
    Brain; 2012 Jun; 135(Pt 6):1860-70. PubMed ID: 22561644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What factors influence motor complications in Parkinson disease?: a 10-year prospective study.
    García-Ruiz PJ; Del Val J; Fernández IM; Herranz A
    Clin Neuropharmacol; 2012; 35(1):1-5. PubMed ID: 22139623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease.
    Weisscher N; Post B; de Haan RJ; Glas CA; Speelman JD; Vermeulen M
    Neurology; 2007 Dec; 69(23):2155-61. PubMed ID: 18056579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors and course of health-related quality of life in Parkinson's disease.
    Forsaa EB; Larsen JP; Wentzel-Larsen T; Herlofson K; Alves G
    Mov Disord; 2008 Jul; 23(10):1420-7. PubMed ID: 18512757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of dysprosody in Parkinson's disease over time--a longitudinal study.
    Skodda S; Rinsche H; Schlegel U
    Mov Disord; 2009 Apr; 24(5):716-22. PubMed ID: 19117364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voiding dysfunction in patients with Parkinson's disease: impact of neurological impairment and clinical parameters.
    Sammour ZM; Gomes CM; Barbosa ER; Lopes RI; Sallem FS; Trigo-Rocha FE; Bruschini H; Srougi M
    Neurourol Urodyn; 2009; 28(6):510-5. PubMed ID: 19191278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants.
    Fasano A; Romito LM; Daniele A; Piano C; Zinno M; Bentivoglio AR; Albanese A
    Brain; 2010 Sep; 133(9):2664-76. PubMed ID: 20802207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of aging to the severity of different motor signs in Parkinson disease.
    Levy G; Louis ED; Cote L; Perez M; Mejia-Santana H; Andrews H; Harris J; Waters C; Ford B; Frucht S; Fahn S; Marder K
    Arch Neurol; 2005 Mar; 62(3):467-72. PubMed ID: 15767513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.